Ocular Hypertension R&D Pipeline Analysis Report, H2-2018

August 2018 | 100 pages | ID: O1A8891DE9DEN
VPAResearch

Abstracts

Ocular Hypertension Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Ocular Hypertension pipeline products.

The Ocular Hypertension pipeline guide presents complete overview of drugs currently being developed for Ocular Hypertension. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Ocular Hypertension pipeline candidate.

Research and Development progress along with latest news related to each of the Ocular Hypertension pipeline candidates is included.

• Major companies participating in therapeutic development of Ocular Hypertension are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.
• Amid strong interest for cure of Ocular Hypertension from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Ocular Hypertension clinical and pre clinical products.
• The report assists in identifying potential upcoming companies and drugs in Ocular Hypertension pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
• Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF OCULAR HYPERTENSION PIPELINE REPORT INCLUDES

• Panorama of Ocular Hypertension pipeline markets including statistics on therapeutic drugs and companies involved
• Ocular Hypertension Pipeline candidates across various development phases including both pre clinical, discovery and clinical stages are covered
• Ocular Hypertension pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
• Overview of companies participating in Ocular Hypertension pipeline with short introduction to their businesses and pipeline projects
• For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co developer and licensee are provided.
• Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Ocular Hypertension pipeline therapeutics

REASONS TO BUY

• Get clear understanding of the entire Ocular Hypertension pipeline, with details on active projects
• Get in detail information of each product with updated information on each project along with key milestones
• Know the list of companies participating in global Ocular Hypertension pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Please Note: The report will be delivered in 2 working days after purchase

Contents

I. KEY FINDINGS

1. Companies Investing in Ocular Hypertension Pipeline include
  Number of Companies with Ocular Hypertension projects in pre clinical Development
  Number of Companies with Ocular Hypertension projects in Clinical Development
  Ocular Hypertension Pipeline Companies based in Americas
  Ocular Hypertension Pipeline Companies based in Europe
  Ocular Hypertension Pipeline Companies based in Asia Pacific
  Ocular Hypertension Pipeline Companies based in Rest of the World
2. Pipeline Candidates include
  Ocular Hypertension Pipeline Agents in pre clinical/Discovery stage of Development
  Ocular Hypertension Pipeline Agents in Clinical Development stage
  Ocular Hypertension Pipeline Therapeutic Compounds received special status
  Mechanism of Action of most pipeline Drugs
  Small molecules among the Ocular Hypertension Pipeline agents

II. INSIGHTS INTO OCULAR HYPERTENSION PIPELINE

1. Disease Overview
  Introduction to Ocular Hypertension
  Symptoms and Causes of Ocular Hypertension
  Treatment or Prevention Options for Ocular Hypertension
  Other Details
2. Phase wise Pipeline Compounds
  Ocular Hypertension Pipeline Pre Clinical/Discovery stage Drugs
  Ocular Hypertension Pipeline Phase 1 stage Drugs
  Ocular Hypertension Pipeline Phase 2 stage Drugs
  Ocular Hypertension Pipeline Phase 3 stage Drugs
  Ocular Hypertension Pipeline Pre Registration stage Drugs
3. Company wise Ocular Hypertension Pipeline Compounds
4. Ocular Hypertension Pipeline by Mechanism of Action

III. OCULAR HYPERTENSION PIPELINE COMPOUND DETAILS

Drug Details
1. Snapshot
  Name of the Therapeutic Agent
  Originator
  Developing Company
  Co Developer/License Partner
  Orphan Drug/Fast Track/Designation
  Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. OCULAR HYPERTENSION PIPELINE COMPANY BRIEFS

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL OCULAR HYPERTENSION PIPELINE MARKET

VI. APPENDIX

1. About Us
2. Research Methodology
3. Contact Information

The report will be delivered within 2 working days after procurement. Some of the sections depicted above may be modified in accordance with relevancy and availability